Trebicka, Jonel

Baveno VII – Renewing consensus in portal hypertension

de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J. G., Albillos, A., Baiges, A., Bajaj, J., Bañares, R., et al. (2022) · Journal of Hepatology

Liver Disease and TransplantationLiver Disease Diagnosis and Treatment

Cited by 2,930

A faecal microbiota signature with high specificity for pancreatic cancer

Kartal, E., Schmidt, T. S. B., Molina-Montes, E., Rodríguez-Perales, S., Wirbel, J., Maistrenko, O. M., Akanni, W. A., Alashkar Alhamwe, B., Alves, R. J., Carrato, A., et al. (2022) · Gut

Gut microbiota and healthPancreatic and Hepatic Oncology Research

Cited by 290

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology

Liver Disease and TransplantationLiver physiology and pathology

Cited by 258

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports

Liver physiology and pathologyDrug-Induced Hepatotoxicity and Protection

Cited by 236

Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment

Schneider, K. M., Mohs, A., Gui, W., Galvez, E. J. C., Candels, L. S., Hoenicke, L., Muthukumarasamy, U., Holland, C. H., Elfers, C., Kilic, K., et al. (2022) · Nature Communications

Gut microbiota and healthImmune cells in cancer

Cited by 225

The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

Verbeke, L., Farre, R., Verbinnen, B., Covens, K., Vanuytsel, T., Verhaegen, J., Komuta, M., Roskams, T., Chatterjee, S., Annaert, P., et al. (2015) · The American Journal of Pathology

Drug Transport and Resistance MechanismsLiver Disease and Transplantation

Cited by 225

Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study

Nagata, N., Nishijima, S., Kojima, Y., Hisada, Y., Imbe, K., Miyoshi-Akiyama, T., Suda, W., Kimura, M., Aoki, R., Sekine, K., et al. (2022) · Gastroenterology

Gut microbiota and healthPancreatic and Hepatic Oncology Research

Cited by 209

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

Pose, E., Napoleone, L., Amin, A., Campion, D., Jimenez, C., Piano, S., Roux, O., Uschner, F. E., de Wit, K., Zaccherini, G., et al. (2020) · The Lancet Gastroenterology & Hepatology

Liver Disease and TransplantationLiver Disease Diagnosis and Treatment

Cited by 154

Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

Solà, E., Pose, E., Campion, D., Piano, S., Roux, O., Simon-Talero, M., Uschner, F., de Wit, K., Zaccherini, G., Alessandria, C., et al. (2021) · Journal of Hepatology

Liver Disease and TransplantationStatistical Methods in Clinical Trials

Cited by 41

Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion

Yu, X., Elfimova, N., Müller, M., Bachurski, D., Koitzsch, U., Drebber, U., Mahabir, E., Hansen, H. P., Friedman, S. L., Klein, S., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology

Liver physiology and pathologyMicroRNA in disease regulation

Cited by 27